Travel vaccines and elderly persons: Review of vaccines available in the United States

Clinical Infectious Diseases

Volumn 33, Issue 9, 2001, Pages 1553-1566

  Leder, Karin ^a,b   Weller, Peter F ^a,b   Wilson, Mary E ^b,c,d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MOUNT AUBURN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIKEN; HEPATITIS A VACCINE; JAPANESE ENCEPHALITIS VACCINE; NEUTRALIZING ANTIBODY; RABIES VACCINE; STAMARIL; TYPHOID VACCINE; YELLOW FEVER VACCINE;

AGING; ANAPHYLAXIS; CONFUSION; DEVELOPING COUNTRY; DRUG HYPERSENSITIVITY; ENCEPHALITIS; EPIDEMIC ENCEPHALITIS; HEPATITIS A; HUMAN; IMMUNE RESPONSE; KIDNEY FAILURE; PRIORITY JOURNAL; RABIES; REVIEW; SEROCONVERSION; THROMBOCYTOPENIA; TRAVEL; TYPHOID FEVER; UNITED STATES; VACCINATION; YELLOW FEVER;

AGED; HEALTH SERVICES FOR THE AGED; HEPATITIS A VACCINES; HUMANS; JAPANESE ENCEPHALITIS VACCINES; RABIES VACCINES; TRAVEL; TYPHOID-PARATYPHOID VACCINES; UNITED STATES; VACCINATION; YELLOW FEVER VACCINE;

EID: 0035503457     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/322968     Document Type: Review

References (121)

1. The immunology of exceptional individuals: The lesson of centenarians
2. Humoral immunity in aging
3. Immune senescence: Mechanisms and clinical implications
4. A cumulative review of studies on travellers, their experience of illness and the implications of these findings
5. Health problems in a large cohort of Americans traveling to developing countries
6. Pre-travel health, immunization status, and demographics of travel to the developing world for individuals visiting a travel medicine service
7. Epidemiology, preventive services, and illnesses of international travelers
8. Epidemiology and prevention of hepatitis A in travelers
9. Hepatitis A and Hepatitis B: Risks compared with other vaccine preventable diseases and immunization recommendations
10. Comparison of immunogenicity of two hepatitis A vaccines - VAQTA and HAVRIX - In young adults
11. Efficacy of different doses of immune serum globulin in the prevention of hepatitis A: A three-year prospective study
12. Immunoglobulin prophylaxis for hepatitis A
13. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: Rationale and summary of findings
14. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children
15. Protection against hepatitis A by an inactivated vaccine
16. Inactivated hepatitis A vaccine: Reactogenicity, immunogenicity, and long-term antibody persistence
17. Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0-6 schedule)
18. Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later
19. Immunogenicity of an inactivated hepatitis A vaccine in Alaska native children and native and non-native adults
20. Immunogenicity of an inactivated hepatitis A vaccine in Dutch United Nations troops
21. The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults
22. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: An overview
23. Hepatitis A vaccination
24. Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults
25. Simultaneous active and passive immunization against hepatitis A studied in a population of travellers
26. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease
27. Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study
28. Clinical trial with inactivated hepatitis A vaccine and recommendations for its use
29. A dose response study of hepatitis A vaccine in healthy adults who are 30 years old and weigh 77 kg
30. Evaluation of inactivated hepatitis A vaccine in Canadians 40 years of age or more
31. Typhoid fever in the United States, 1985-1994: Changing risks of international travel and increasing antimicrobial resistance
32. Laboratory-based surveillance of Salmonella serotype typhi infections in the United States: Antimicrobial resistance on the rise
33. Typhoid in the United States and the risk to the international traveler
34. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines
35. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization
36. Typhoid fever vaccines
37. Progress in vaccines against typhoid fever
38. A new typhoid vaccine composed of the Vi capsular polysaccharide
39. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines
40. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever
41. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: A preliminary report
42. Typhoid vaccination: Weighing the options
43. Typhoid fever vaccines: A meta-analysis of studies on efficacy and toxicity
44. Inefficacy of the commercial live oral Ty 21a vaccine in the prevention of typhoid fever
45. Typhoid fever in group travelers: Opportunity, for studying vaccine efficacy
46. Fatal yellow fever in a traveler returning from Venezuela, 1999
47. Fatal yellow fever in a traveler returning from Venezuela, 1999
48. Imported yellow fever in a United States citizen
49. A haemorrhagic fever from the Cote d'Ivoire
50. Yellow fever: A decade of reemergence
51. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines
52. Yellow fever
53. Anaphylaxis from yellow fever vaccine
54. Yellow fever I7D vaccine virus isolated from healthy vaccinees accumulates very few mutations
55. Yellow fever vaccines
56. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine
57. Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines
58. Immunological studies with group B arthropod-borne viruses. V. Evaluation of cross-immunity against type 1 dengue fever in human subjects convalescent from subclinical natural Japanese encephalitis virus infection and vaccinated with 17D strain yellow fever vaccine
59. Immunological studies with group B arthropod-borne viruses. VI. Hemagglutination-inhibiting antibody responses to 17D yellow fever vaccine in human subjects with different degrees of complexity of pre-vaccination group B virus experience
60. Heterotypic serologic responses after yellow fever vaccination: Detection of persons with past St. Louis encephalitis or dengue
61. Advanced age as a risk factor for illness temporally associated with yellow fever vaccination
62. Travel-related vaccines
63. Inactivated Japanese encephalitis virus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
64. Immunisation against Japanese encephalitis
65. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): A case-control study
66. A field trial of Japanese encephalitis vaccine produced in Thailand
67. Japanese encephalitis vaccine and adverse effects among travellers
68. A cluster of severe reactions following improperly administered Takeda Japanese encephalitis vaccine
69. Acute disseminated encephalomyelitis after Japanese B encephalitis vaccination
70. Acute disseminated encephalomyelitis after treatment with Japanese B encephalitis vaccine (Nakayama-Yoken and Beijing strains)
71. Neurological complications to vaccination against Japanese encephalitis
72. Side-effects with Japanese encephalitis vaccine
73. Systemic reactions in US Marine Corps personnel who received Japanese encephalitis vaccine
74. Enzyme-linked immunosorbent assay for detection of serum antibody in children vaccinated with Japanese encephalitis vaccine
75. Neutralizing antibody responses to Japanese encephalitis vaccine in children
76. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants
77. Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis vaccine: A comparison of 1- and 3-month immunization schedules
78. A field study on Nakayama and Beijing strains of Japanese encephalitis vaccines
79. Further experience with Japanese encephalitis vaccine
80. Japanese encephalitis vaccine (inactivated, BIKEN) in U.S. soldiers: Immunogenicity and safety of vaccine administered in two dosing regimens
81. Immunisation against Japanese encephalitis in Nepal: Experience of 1152 subjects
82. Japanese encephalitis vaccine
83. Protection against Japanese encephalitis by inactivated vaccines
84. A field trial with an improved Japanese encephalitis vaccine in a nonendemic area of the disease
85. Case-control study of allergic reactions to Japanese encephalitis vaccine
86. Human rabies prevention - United States, 1999: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
87. Antibody responses to human diploid cell vaccine for rabies with and without human rabies immune globulin
88. Some experiences with human diploid cell strain (HDCS) rabies vaccine in pre- and post-exposure vaccinated humans
89. Modern vaccines: Rabies
90. Longevity of rabies antibody titre in recipients of human diploid cell rabies vaccine
91. A global review of rabies vaccines for human use
92. Additional reports of failure to respond to treatment after rabies exposure in Thailand
93. Immune response of the elderly to rabies vaccines
94. Antibody response to rabies vaccine prepared in tissue cultures of human diploid cells and inactivated, evaluated in different classes of age
95. Rabies postexposure prophylaxis with human diploid cell rabies vaccine: Lower neutralizing antibody titers with Wyeth vaccine
96. Evaluation of a human diploid cell strain rabies vaccine: Final report of a three year study of pre-exposure immunization
97. Immunogenicity and acceptability of a human diploid-cell culture rabies vaccine in volunteers
98. Immunization with a human diploid cell strain of rabies virus vaccine: Two-year results
99. Human rabies immunoprophylaxis using HDC (MRC-5) vaccine
100. Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-Year follow-up and proposal for a new booster policy
101. Rhesus diploid rabies vaccine (adsorbed), a new rabies vaccine: Results of initial clinical studies of preexposure vaccination
102. Predictive factors for the neutralizing antibody response following pre-exposure rabies immunization: Validation of a new booster dose strategy
103. Immunogenicity of purified duck embryo rabies vaccine (Lyssavac-N) with use of the WHO-approved intradermal postexposure regimen
104. Risk factors for systemic hypersensitivity reactions after booster vaccinations with human diploid cell rabies vaccine: A nationwide prospective study
105. Responses to tuberculin and meningococcal polysaccharide vaccination during ageing in Nigerians
106. Combined vaccination against yellow fever and typhoid fever: A comparative trial
107. Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide vaccine in South African school children ten years after immunization
108. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever
109. Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children
110. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation
111. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial
112. Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults
113. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine
114. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial
115. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine
116. A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: Three-year results
117. The human humoral immune response to Salmonella typhi Ty21a
118. The effect of chloroquine prophylaxis on yellow fever vaccine antibody response: Comparison of plaque reduction neutralization test and enzyme-linked immunosorbent assay
119. Response to JE vaccine among HIV-infected children, Bangkok, Thailand
120. Japanese encephalitis vaccine: Persistence of antibody up to 3 years after a three-dose primary series
121. Rabies vaccine